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Staging of endometrial cancer with MRI:
Guidelines of the European Society
of Urogenital Imaging
Abstract The purpose of this study
was to define guidelines for endome-
trial cancer staging with MRI. The
technique included critical review and
expert consensus of MRI protocols by
the female imaging subcommittee of
the European Society of Urogenital
Radiology, from ten European insti-
tutions, and published literature be-
tween 1999 and 2008. The results
indicated that high field MRI should
include at least two T2-weighted
sequences in sagittal, axial oblique or
coronal oblique orientation (short and
long axis of the uterine body) of the
pelvic content. High-resolution post-
contrast images acquired at 2min ± 30 s
after intravenous contrast injection
are suggested to be optimal for the
diagnosis of myometrial invasion. If
cervical invasion is suspected, addi-
tional slice orientation perpendicular
to the axis of the endocervical channel
is recommended. Due to the limited
sensitivity of MRI to detect lymph
node metastasis without lymph node-
specific contrast agents, retroperito-
neal lymph node screening with
pre-contrast sequences up to the level
of the kidneys is optional. The like-
lihood of lymph node invasion and
the need for staging lymphadenectomy
are also indicated by high-grade his-
tology at endometrial tissue sampling
and by deep myometrial or cervical
invasion detected by MRI. In conclu-
sion, expert consensus and literature
review lead to an optimized MRI
protocol to stage endometrial cancer.
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Introduction
Endometrial cancer is the fourth most frequent cancer in
women and now the most common gynecological cancer in
many developed countries [1]. Surgical treatment options
depend on the local extent of disease [2, 3]. In low-risk
patients only hysterectomy with bilateral oophorectomy is
performed, whereas in selected high-risk patients lym-
phadenectomy, omental and peritoneal biopsies are in-
cluded in the surgical treatment [4]. The most recent
surgical trend consists in performing lymphadenectomy
through laparoscopy [5]. The disadvantage of systematic
lymphadenectomy is a 7–10% risk of lymph cyst formation
after surgery [5, 6], increased anesthesia and operating
time, and the need for a specialized oncologic surgeon.
However, when lymphadenectomy is not performed, most
patients will undergo either a second surgery with pelvic
lymphadenectomy when pathology of the uterus reports
deep myometrial or cervical invasion, or a systematic
pelvic or intravaginal postoperative radiation therapy.
Pelvic radiation therapy might not be necessary if prior
lymphadenectomy has not shown lymph node invasion [7].
Patient selection for primary lymphadenectomy at the time
of hysterectomy is therefore a current debate in oncological
gynecology [4].
In patients with endometrial cancer, histological tumor
grade and depth of myometrial invasion strongly correlate
with lymph node metastases and patient survival [8].
Therefore, patients are considered at high risk for lymph
node invasion when high tumor grade is diagnosed at
endometrial biopsy or when deep myometrial invasion is
identified before surgery. A meta-analysis of reported MRI
studies suggests that preoperative identification of deep
myometrial invasion in patients with endometrial cancer is
best performed with contrast-enhanced MRI of the pelvis
with an accuracy of about 91% [9]. Without the use of
contrast-enhanced MRI and using only the knowledge of
preoperative tumor grade from the endometrial biopsy, the
probability of deep endometrial invasion has been
estimated at respectively 13% for tumor grade 1, 35% for
tumor grade 2 and 54% for tumor grade 3 [10]. After a
positive MRI for deep myometrial invasion, those
probabilities change to respectively 60, 84 and 92% for
tumor grade 1, 2 and 3. When MRI of the pelvis does not
identify deep myometrial invasion, the probability of such
a condition decreases to respectively 1, 5 and 10% for
tumor grade 1, 2 and 3 [10]. However pitfalls in diagnosing
the extent of endometrial cancer have been reported with
MRI when associated adenomyosis or large leiomyoma
impairs exact assessment of the depth of myometrial
invasion [11, 12]. To reduce potential pitfalls or mis-
interpretation of false-negative or false-positive findings of
myometrial or cervical invasion, MRI images should be
acquired with enough technical quality to allow adequate
image interpretation. Many of the studies analyzed in the
meta-analysis [9] were small series reported from the
proving stage of MRI, and some revealed low image
quality and a lack of technical standards. Thus, the female
pelvis subcommittee of the European Society of Urogenital
Imaging (ESUR) formed a working group to establish
technical guidelines for endometrial cancer staging with
MRI based on extended clinical practice.
Material and methods
MRI protocols for staging endometrial cancer were
collected from ten European institutions. Inclusion criteria
to participate in the guidelines topic “Staging endometrial
cancer with MRI” were: to be a member of the European
Society of Urogenital Imaging (ESUR) and to perform at
least ten MR imaging examinations per year for staging
biopsy-proven endometrial carcinoma. The questionnaire
included the following details: field strength and type of
coil, patient preparation, type of sequence with detailed
geometry and contrast information, such as FOV, matrix
scan and reconstruction, slice thickness, gap, orientation,
saturation bands, 2D versus 3D sequence, TR/TE, number
of acquisitions, number and lengths of dynamic sequences,
bolus IV injection and use of subtraction techniques. In
addition, published literature between 1999 and 2008 was
reviewed through a Medline literature search of abstracts in
the English language on studies in human subjects,
including the following key words: “Uterine neoplasm(s)
AND MR imaging” or “Endometrial carcinoma AND MR
imaging.” Articles that did not include technical details
following the information of the questionnaire were
excluded. The results were presented in an excel sheet
including descriptive statistics, and were discussed and
divided in topics with agreement and disagreement. Topics
with disagreement were conpared to the literature. Experts
in favor of one technical option were asked to document
their point of view with the corresponding literature, which
was discussed by an expert panel. Literature work was
compared taking into consideration year of publication,
number of cases and performance of the technique. When
technical details varied and no published work on
performance was found, the subject was discussed and
resolved in consensus based on the majority of participat-
ing members. Members of the group met twice a year
during a 2-year period and were asked to apply technical
recommendations issued after the first two meetings during
year 1 before the meetings in year 2 to allow further
discussion and making final conclusions in consensus.
Results
Technical consideration with agreement
Among the ten ESURmembers, seven worked at 1.5 T, two
at 1.0 T and one institution at 0.5 T. Agreement concerned
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fasting (3–6 h) and intramuscular injection of peristaltic
inhibitors (1 mg glucagon or 20 mg butyl-scopolamine)
unless contraindicated (e.g., diabetes or pheochromocyto-
ma) to decrease peristalsis artifacts. Furthermore, there was
consensus to apply anterior and superior saturation bands
and to use a combination of at least two T2-weighted
unenhanced (TR/TE 4,000/90 ms) and one T1-weighted
enhanced sequence for the assessment of myometrial
invasion. Oblique coronal and axial slice orientation
according to the long and short axis of the endometrial
cavity should be applied under medical supervision as
technicians might not have sufficient anatomical knowl-
edge to clearly identify the long axis of the uterine body
(although with adequate training this should become
possible). For optimal image quality, T2-weighted images
covering the pelvis should be acquired with a small FOV
(20–25 cm) and ideally with a 512×512 matrix. Slice
sections of 4 mm in T2-weighted imaging should avoid
difficulties in analyzing small postmenopausal uteri or
underestimation of myometrial depth invasion because of
thin overstretched myometrial walls by large tumors.
Disruption of the junctional zone at T2-weighted images
or discontinuity on early subendometrial contrast enhance-
ment on dynamic imaging has been described as a
landmark for the diagnosis of myometrial invasion [13–
16] (Fig. 1). However, this finding is typically not seen in
the menstrual and first part of the cycle. Furthermore, in
women at postmenopausal age where such an enhancement
pattern is reported as typical, its visualization may be
impaired by the low spatial resolution of dynamic contrast-
enhanced imaging [17, 18]. Slice section of 2 mm with
enough spatial resolution is only possible in 3D gradient
echo sequences, which may be preferable to standard
enhanced 2D sequences.
As lymph node metastases may skip the pelvis and occur
primarily in the para-aortic region, the retroperitoneum
should be included in the imaging protocol. This protocol
option has the advantage of allowing simultaneous
detection of hydronephrosis. Table 1 shows the results of
the literature search, including technical protocols.
Fig. 1 a: Figure 1: MRI of the pelvis in a 75-year-old patient with
biopsy-proven endometrial carcinoma grade 2. (a) Sagittal T2-
weighted image of the uterus demonstrates an enlarged hyperintense
endometrium with an interruption of the low signal intensity of the
posterior junctional zone (arrow), suggesting myometrial invasion.
(b) The axial oblique T2-weighted image of the uterus, perpendi-
cular to the direction of the cavity seen in (a) and passing through
the interrupted juntional zone, demonstrates heterogeneous signal
intensity of the upper junctional zone (arrow) without evidence of
deep endometrial invasion. (c) The 3D contrast-enhanced gradient
echo image with fat suppression acquired 2 min after contrast
injection confirms a heterogeneous interface between the less
enhancing endometrial cancer and the strongly enhancing normal
myometrium, suggesting superficial mymometrial invasion. Stage
IB was confirmed at histopathology; 50×50 mm (300×300 DPI). b:
Figure 1: MRI of the pelvis in a 75-year-old patient with biopsy-
proven endometrial carcinoma grade 2. (a) Sagittal T2-weighted
image of the uterus demonstrates an enlarged hyperintense endo-
metrium with an interruption of the low signal intensity of the
posterior junctional zone (arrow), suggesting myometrial invasion.
(b) The axial oblique T2-weighted image of the uterus, perpendi-
cular to the direction of the cavity seen in (a) and passing through
the interrupted juntional zone, demonstrates heterogeneous signal
intensity of the upper junctional zone (arrow) without evidence of
deep endometrial invasion. (c) The 3D contrast-enhanced gradient
echo image with fat suppression acquired 2 min after contrast
injection confirms a heterogeneous interface between the less
enhancing endometrial cancer and the strongly enhancing normal
myometrium, suggesting superficial mymometrial invasion. Stage
IB was confirmed at histopathology; 50×50 mm (300×300 DPI).
(c): Figure 1: MRI of the pelvis in a 75-year-old patient with biopsy-
proven endometrial carcinoma grade 2. (a) Sagittal T2-weighted
image of the uterus demonstrates an enlarged hyperintense endo-
metrium with an interruption of the low signal intensity of the
posterior junctional zone (arrow), suggesting myometrial invasion.
(b) The axial oblique T2-weighted image of the uterus, perpendi-
cular to the direction of the cavity seen in (a) and passing through
the interrupted juntional zone, demonstrates heterogeneous signal
intensity of the upper junctional zone (arrow) without evidence of
deep endometrial invasion. (c) The 3D contrast-enhanced gradient
echo image with fat suppression acquired 2 min after contrast
injection confirms a heterogeneous interface between the less
enhancing endometrial cancer and the strongly enhancing normal
myometrium, suggesting superficial mymometrial invasion. Stage
IB was confirmed at histopathology; 50×50 mm (300×300 DPI)
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Discordance concerning dynamic post-contrast
sequences
A single discordant topic concerned the type of contrast-
enhanced T1-weighted sequences: 2D versus 3D sequence,
a single or up to eight dynamic acquisitions after intrave-
nous contrast medium, as well as the length of a single
dynamic acquisition that varied between 18 s and 3 min 21 s.
Dynamic image acquisition has been recommended since
Yamashita et al. in 1993, observing less contrast between
the tumor and the normal myometrium at 5 min after
injection of contrast agent compared to 2 min after
injection [13]. The authors demonstrated that at dynamic
imaging acquired every 30 s, normal myometrium showed
strong early enhancement at 90 s after bolus enhancement,
particularly at the junctional zone. The tumor invading the
myometrium demonstrated decreased enhancement com-
pared to the strong enhancement of normal myometrium.
The greatest contrast between invaded and non-invaded
myometrium was visible at 2 min after injection. Most
publications after 1993 therefore presented imaging
protocols with dynamic enhancement. In 2004, Manfredi
et al. demonstrated an optimal contrast-to-noise ratio
between the endometrial tumor and the normal myometri-
um at 2 min 30 s compared to 30 s and 1 min 30 s after
intravenous injection of contrast agent [28]. The imaging
protocol used a dynamic 3D gradient echo sequence
(FMSPGR) with one unenhanced and three enhanced
acquisitions of 1-min acquisition time each. A quantitative
analysis of the contrast-to-noise ratio between the endo-
metrial tumor and the normal myometrium was performed
through a region-of-interest analysis at a workstation.
A discussion was raised about the utility of dynamic
acquisition due to the newly proposed optimal time point of
2 min 30 s that could be obtained with a single enhanced
acquisition with higher spatial resolution. Reported false-
negative findings of deep myometrial invasion in small
uteri could be due to a technical protocol that chose a
decreased spatial resolution of dynamic imaging in favor of
higher temporal resolution to allow dectection of the
optimal time point of strong myometrial enhancement. To
avoid understaging of endometrial carcinoma due to an
overstretched myometrium by tumor distention of the
cavity, smaller slice thickness, field of view and higher
matrix are technical solutions to decrease the occurrence of
these pitfalls [12]. Associated benign uterine disease can be
responsible for overstaging of myometrial invasion due to
hypovascular myomas or adenomyosis mimicking deep
endometrial invasion (Figs. 2 and 3). If endometrial polyps
are present in the endocervical channel, cervical invasion
Table 1 Results of the literature
search according to year of
publication
First author Journal Year Literature reference
Cabrita Eur J Gynaecol Oncol 2008 [19]
Shen AJR 2008 [20]
Park Gyn Oncol 2008 [21]
Ortashi EJOG 2008 [22]
Sala AJR 2007 [23]
Chung Gyn Oncol 2007 [24]
Nakao Gyn Oncol 2006 [25]
Messiou Clinical Radiology 2006 [18]
Barwick Clinical Radiology 2006 [26]
Nasi Radiol Med 2005 [27]
Manfredi Abdom Imaging 2005 [14]
Manfredi Radiology 2004 [28]
Utsunomiya AJR 2004 [29]
Tanaka Eur Radiol 2003 [30]
Ohguri Eur Radiol 2002 [15]
Cunha Int J Gynecol Cancer 2001 [31]
Ueda Eur Radiol 2001 [32]
Grasel Radiology 2000 [33]
Kinkel Radiology 1999 [9]
Shibutani Abdom Imaging 1999 [34]
Joja Radiat Med 1999 [16]
Lee Radiographics 1999 [35]
Koyama AJR 1999 [36]
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can be overdiagnosed. A single high spatial resolution 3D
gradient echo sequence was suggested as the optimal
enhanced sequence for the diagnosis of myometrial
invasion by endometrial cancer. The increased length of
those sequences usually allows selective fat suppression
during image acquisition and a matrix of 512×512 that
should increase detection of deep myometrial invasion and
allow the diagnosis of transmyometrial invasion (invasion
up to the uterine serosa, stage IIIA) with higher confidence.
Because of rectilinear k-space sampling in the y
direction during 3D sequences, the signal intensity of the
first commercially available 3D sequences corresponded to
the contrast acquisition at the middle of the acquisition time
(for example, 2 min 30 s for a single 3D sequence with an
acquisition time of 5 min for GE). This sampling time
might be earlier and vary according the magnet constructor
and the magnet version. In more recently developed 3D fat-
suppressed angiographic sequences, such as the THRIVE
(Philips), VIBE (Siemens) or VIBRANT (GE) sequence,
the time point used to acquire sequence information
relative to contrast corresponds to 20% of the acquisition
time, depending for the same sequence also on the magnet
and the software version. Let’s check the timing of
intravenous contrast injection in two different centers in
which the radiologist wants to acquire post-contrast images
at 2 min after contrast injection with two different 3D
sequences of the same acquisition time: For a 3D sequence
of 4 min 10 s acquisition time (250 s) and an image contrast
acquisition at 20% of acquisition time (at 50 s), the
intravenous contrast agent should be injected 70 s prior to
acquisition start to allow collection of contrast information
at 120 s. If a 3D sequence of 4 min 10 s has a time point that
acquires sequence information relative to contrast at mid-
sequence acquisition time (2 min 5 s), the intravenous
contrast can be injected 5 s after acquisition start. This
example demonstrates the importance of communication
with the application specialist of the magnet to know when
information relative to the contrast is acquired during
acquisition time for a specific 3D sequence, magnet and
software version, therefore allowing adequate timing of
intravenous injection of contrast agents. A summary of the
technical protocol recommendation is presented in Table 2.
Criteria for image interpretation according to tumor stage
The MR staging criteria for endometrial cancer follows the
guidelines of the surgically-pathologically based FIGO
classification [26, 37]. Stage O tumors (carcinoma in situ)
are not visualized on MRI. In stage I endometrial cancer,
the tumor is limited to the uterine corpus. It encompasses
tumor without myometrial invasion (stage IA), super-
ficially (IB) and deeply (IC) invasive cancers of the
myometrium. In stage IA normal, diffusely or focally
thickened endometrium larger than 3 mm in postmeno-
pausal age may be seen. The key feature in imaging is
identification of the intact low signal intensity junctional
zone at T2-weighted imaging. At T1-weighted dynamic
Fig. 2 (a): Figure 2: MRI of the pelvis in a 70-year-old patient with
grade 3 endometrial carcinoma. (a) Sagittal T2-weighted image of
the uterus shows a thin endometrial cavity and a thickened
junctional zone containing hyperintense lines (arrow), suggesting
adenomyosis. Identification of the endometrial tumor is difficult. (b)
The sagittal contrast-enhanced 3D gradient echo image with fat
suppression acquired at 2 min after contrast injection demonstrates a
hypointense area extending from the uterine cavity up to the outer
myometrium (arrow), diagnosing deep endometrial invasion beyond
the area of associated adenomyosis. Stage 1C with adenomyosis was
confirmed at histopathology; 50×50 mm (300×300 DPI). (b):
Figure 2: MRI of the pelvis in a 70-year-old patient with grade 3
endometrial carcinoma. (a) Sagittal T2-weighted image of the uterus
shows a thin endometrial cavity and a thickened junctional zone
containing hyperintense lines (arrow), suggesting adenomyosis.
Identification of the endometrial tumor is difficult. (b) The sagittal
contrast-enhanced 3D gradient echo image with fat suppression
acquired at 2 min after contrast injection demonstrates a hypointense
area extending from the uterine cavity up to the outer myometrium
(arrow), diagnosing deep endometrial invasion beyond the area of
associated adenomyosis. Stage 1C with adenomyosis was confirmed
at histopathology; 50×50 mm (300×300 DPI)
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Table 2 Suggested MR imaging protocol for staging endometrial cancer
Patient preparation and positioning:
Fasting: 3–6 h
Antiperistaltic agent if not contraindicated
Supine position
Pelvic phased-array coil
T2-weighted imaging:
Image orientation: Sagittal, axial oblique (perpendicular) and coronal oblique (parallel) to the uterine cavity. If cervical involvement is
suspected, additional axial oblique image orientation perpendicular to the long axis of the endocervical channel
Slice thickness for the pelvis: ≤4 mm, FOV 20–25 cm. High-resolution matrix (512 × 512)
Extended FOV for assessing the retroperitoneum with coronal T1-weighted or axial T2-weighted sequence with fat suppression
Contrast-enhanced imaging
Suggested for higher accuracy of the diagnosis of deep myometrial invasion. Recommended for atrophic uteri, associate adenomyosis or
fibroids, or in suspected advanced tumors (suspicious bladder or rectal wall invasion)
2D or 3D techniques may be performed with the optimal tumor/myometrial contrast timing between 90 and 150 s. A single 3D
acquisition technique seems a good alternative to dynamic imaging as it combines a high tumor-myometrium contrast with multiplanar
reformations and thin slice sections
Fig. 3 (a): Figure 3: MRI of the pelvis in a 56-year-old patient with
grade 1 endometrial cancer and an enlarged uterine size at pelvic
sonography. (a) Sagittal T2-weighted image of the uterus demon-
strates multiple submucosal and interstitial leiomyoma associated
with an enlarged uterine cavity and a small interruption of the
anterior junctional zone (arrow), suggesting superficial myometrial
invasion. (b) An axial oblique image of the upper uterine cavity
shows no junctional zone because of multiple submucosal leiomy-
oma protruding into the cavity. (c) Contrast-enhanced 3D gradient
echo image with fat suppression in the same orientation as in image
(b) shows an enhancing line (arrow) between the submucosal
leiomyomas and the endometrial tumor associated with a slight
decrease in visibility of the line at the right side. Histopathology of
the hysterectomy specimen demonstrated superficial myometrial
invasion of the uterus (stage IB); 50×50 mm (300×300 DPI). (b):
Figure 3: MRI of the pelvis in a 56-year-old patient with grade 1
endometrial cancer and an enlarged uterine size at pelvic sonogra-
phy. (a) Sagittal T2-weighted image of the uterus demonstrates
multiple submucosal and interstitial leiomyoma associated with an
enlarged uterine cavity and a small interruption of the anterior
junctional zone (arrow), suggesting superficial myometrial invasion.
(b) An axial oblique image of the upper uterine cavity shows no
junctional zone because of multiple submucosal leiomyoma
protruding into the cavity. (c) Contrast-enhanced 3D gradient echo
image with fat suppression in the same orientation as in image (b)
shows an enhancing line (arrow) between the submucosal leiomy-
oma and the endometrial tumor associated with a slight decrease in
visibility of the line at the right side. Histopathology of the
hysterectomy specimen demonstrated superficial myometrial invasion
of the uterus (stage IB); 50×50mm (300×300DPI). (c): Figure 3:MRI
of the pelvis in a 56-year-old patient with grade 1 endometrial
cancer and an enlarged uterine size at pelvic sonography. (a) Sagittal
T2-weighted image of the uterus demonstrates multiple submucosal
and interstitial leiomyoma associated with an enlarged uterine cavity
and a small interruption of the anterior junctional zone (arrow),
suggesting superficial myometrial invasion. (b) An axial oblique
image of the upper uterine cavity shows no junctional zone because
of multiple submucosal leiomyoma protruding into the cavity. (c)
Contrast-enhanced 3D gradient echo image with fat suppression in
the same orientation as in image (b) shows an enhancing line
(arrow) between the submucosal leiomyoma and the endometrial
tumor associated with a slight decrease in visibility of the line at the
right side. Histopathology of the hysterectomy specimen demonstrated
superficial myometrial invasion of the uterus (stage IB); 50×50 mm
(300×300 DPI)
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imaging complete subendometrial enhancement may be
visible. If the junctional zone is not visible, a sharp tumor-
myometrial interface at T2-weighted imaging and at
contrast-enhanced images suggests an intact myometrium.
It is not unusual to see minimal abnormality, such as a
small amount of fluid within the endometrial cavity after
diagnostic resection.
Conversely, in stage IB and IC cancer myometrial
invasion is found. In stage IB, which refers to myometrial
invasion of less than half of the myometrial thickness,
disruption or irregularity of the low signal intensity
junctional zone by intermediate signal intensity mass is
identified at T2-weighted imaging (Figs. 1 and 3). If the
junctional zone is not visible, as in up to half of
postmenopausal women or in associated findings, such as
fibroids and adenomyosis, contrast-enhanced MRI helps in
the assessment of the depth of myometrial invasion [9]. In
stage IB at approximately 2 min or 90 to 150 s at contrast-
enhanced imaging, an irregular endometrium/myometrium
interface is best identified [28]. In stage IC the endometrial
cancer extends into the outer half of the myometrium, but a
small stripe of deep normal myometrium is preserved
(Fig. 2).
Stage II endometrial cancer is characterized by tumor
extension into the cervix, but not beyond the uterus. In
stage IIA the internal os and the endocervical canal are
widened by the hyperintense or inhomogeneous tumor
signal at T2-weighted imaging or the hypointense tumor at
contrast-enhanced imaging. If the low signal intensity ring
of the normal cervical stroma is disrupted, stage IIB can be
diagnosed [38, 39] (Fig. 4). Axial oblique image orienta-
tion perpendicular to the cervical canal with thin section
thickness will improve the assessment of cervical invasion
in endometrial cancer [34]. Direct cervical stroma invasion
may occur without invasion of the endocervical mucosa
because of adjacent myometrial invasion. Due to reduced
contrast uptake of the cervical stroma compared to the
myometrium, the contrast resolution between the tumor
and the cervical stroma may be reduced on contrast-
enhanced images.
In stage III tumor extends beyond the uterus, but is
confined to the true pelvis. In stage IIIA transmyometrial
involvement and disruption of the T2 hypointense uterine
serosa and/or irregular uterine contour is noted. Other
findings may include adnexal or parametrial involvement.
Metastases to or direct extension to the upper vagina with
focal loss of the low signal intensity vaginal wall is typical
for stage IIIB. Pelvic and/or para-aortic lympadenopathy
indicates stage IIIC. Imaging signs of lymph node
involvement include a diameter equal to or greater than
8 mm in the pelvis or in round nodes and of greater than
10-mm short axis in retroperitoneal or oval nodes.
Stage IV endometrial cancer is defined by tumor
extension beyond the true pelvis or involvement of the
bladder or rectal mucosa. MRI findings include disruption
of the low signal intensity of the bladder or rectal wall, a
mucosal or intra-luminal mass (stage IVA) best identified
with contrast-enhanced sequences. Distant metastases
(IVB) are rare at presentation and better seen at CT or at
an extended MR imaging protocol to the abdomen.
Abdominal lymph node metastases with the exception of
retroperitoneal and inguinal lymph nodes, signs of perito-
neal spread and metastases to the lungs and liver are found
in stage IVB.
Indications for MRI in endometrial cancer
In comparison to ovarian and cervical cancer, there is a
debate about the usefulness of pretreatment MRI [40]. The
main reason is that endometrial cancer is treated in the
majority of cases by surgery. However, therapeutic options
may vary and depend on tumor stage, tumor grade and
medical condition of the patient. The growing integration
of radiologists in multidisciplinary teams is central in
defining tailored treatment options, and imaging findings
may modify the therapeutic approach [40]. Indications for
MRI with proven or suspected endometrial cancer include:
high grade, serous or clear cell adenocarcinomas; suspicion
of advanced disease, including cervical stroma extension
and confirmation of stage III and IV disease; screening for
lymph node enlargement as a roadmap for lymph node
sampling; medical contraindication for surgical staging;
suspected endometrial cancer with inability of curettage
(e.g., cervical stenosis). The key advantage of MRI is in
demonstrating stage IC disease, outer myometrial invasion
or stage II disease, cervical involvement, in cases that
would otherwise have been understaged or undertreated.
Fig. 4 Sagittal T2-weighted image of the uterus in a 60-year-old
patient with grade 2 endometrial carcinoma. The thickened
hyperintense endometrium invades the mucosa of the endocervical
channel and the adjacent hypointense cervical stroma (arrow). A
large subserosal leiomyoma is identified in the anterior uterine wall
(asterix). Stage IIB was confirmed at histopathology; 50×50 mm
(300×300 DPI)
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Open questions
Preoperative lymph node imaging has been limited by the
low performance of all imaging techniques, including MRI.
Size criteria often do not correlate with histological
findings because of the high frequency of micrometastases
[19]. This is why MRI serves rather as a roadmap for
guiding lymph node sampling than for detecting stage IIIC
endometrial cancer [41]. Assessment of lymph node
invasion in patients with endometrial or cervical cancer
using a lymph node-specific contrast agent, ferumoxtran-
10, composed of ultrasmall particles of iron oxide
(USPIO), increases the sensitivity of lymph node metas-
tasis from 29% to 93% when nanoparticle-enhanced MRI
is performed [42]. The product is evaluated in research
protocols and requires injection 24 h prior to the MRI
examination. Other studies in patients with prostate cancer
have shown that there is no need to perform a MRI study
before and after injection of nanoparticles [43]. Further
consensus is required about how to proceed for staging
MRI for patients with endometrial cancer, including
nanoparticle-enhanced MRI as a one-stop staging exami-
nation. According to Rockall and co-authors, the high
negative predictive value of MR lymphography could
potentially allow avoiding surgical lymph node dissection,
whereas a positive result of MR lymphography could
indicate the site of metastatic nodes to direct surgical
planning or radiation therapy according to the surgical risk
profile of the patient. The commercial availability of
USPIO in the near future is however uncertain.
F18- FDG PET/CT is useful in detecting distant
metastases and in the surveillance of recurrent endometrial
cancer. Its value for staging endometrial cancer is not yet
established. First data show no superiority of PET/CT
compared to MRI in the detection and lymph node
assessment of endometrial cancer [21].
There are some patients for whom lymphadenectomy
will occur on the basis of factors from endometrial
sampling, e.g., high-grade histology, or from basic
MRI, e.g., outer myometrial or cervical invasion. Thus,
newer MR technologies should be used selectively and
after multidisciplinary discussion to avoid unnecessary
expense.
Diffusion- weighted imaging is emerging as a promising
tool in assessing gynecologic cancers. As mean ADC
values of endometrial cancer are lower than that of
myometrium, this technique may aid in assessing myo-
metrial invasion [20]. Further research is required to define
if it should be included as an adjunct sequence in the
preoperative assessment of endometrial cancer.
In conclusion, in patients sent for MR staging of an
endometrial carcinoma, the female imaging subcommittee
of the European Society of Urogenital Radiology sug-
gested the use of at least two T2-weighted sequences
followed by a single enhanced acquisition at optimal image
orientation according to the results of sagittal, oblique short
or long axis T2-weighted images. Selection of imaging
planes requires close medical supervision during image
acquisition. Further research should test the accuracy of a
single high-resolution 3D gradient echo sequence in
patients with endometrial cancer to diagnose myometrial
and stromal invasion and evaluate the clinical utility of
emerging technologies, such as nanoparticle and functional
imaging. Indications for MRI include: high grade, serous or
clear cell adenocarcinomas; suspicion of disease greater
than stage 1B; screening for lymphadenopathy; medical
contraindication for surgical staging; suspected inability of
curettage.
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